ESALF - Biogen Eisai Alzheimer's candidate lecanemab linked to third patient death

• A third patient has died while taking Biogen ( NASDAQ: BIIB ) and Eisai's ( OTCPK:ESALY ) ( OTCPK:ESALF ) experimental Alzheimer's treatment lecanemab and the fatality is being linked to the drug, Science reported.
• The journal said the death was in a 79-year-old woman who experienced extensive brain swelling and bleeding, as well as seizures.
• This is not the first time brain swelling and bleeding has been observed with lecanemab. Brain hemorrhaging was seen in the other two trial deaths as well .
• Science said that based on the woman's health records, she had early Alzheimer's and no obvious health problems.
• The third death comes as the FDA is set to act on the lecanemab BLA by Jan. 6, 2023.
• On Thursday, the Institute for Clinical and Economic Review (ICER) said that for lecanemab to be cost effective, it would need to be priced $9K-$21K per year .

For further details see: